Compugen Ltd
CGEN
Market Cap$201.68M
Close$
$2.54
35.2% upside
Current Fair Value
35.2% upsideUndervalued by 35.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $201.68 Million |
|---|---|
| Enterprise Value | $104.75 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.39 |
| Beta | 2.25 |
| Outstanding Shares | 89,237,465 |
| Avg 30 Day Volume | 275,195 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.99 |
|---|---|
| PEG | 161.22 |
| Price to Sales | - |
| Price to Book Ratio | 1.88 |
| Enterprise Value to Revenue | 17.46 |
| Enterprise Value to EBIT | -3.01 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Compugen Ltd
CEO: Anat Cohen-Dayag Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...